Matches in SemOpenAlex for { <https://semopenalex.org/work/W147146103> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W147146103 endingPage "38" @default.
- W147146103 startingPage "129" @default.
- W147146103 abstract "We have previously reported the superiority of the epirubicin 180 mg/m2-cisplatin combination over single drug epirubicin 180 mg/m2 for advanced soft tissue sarcoma both in terms of response (54% vs. 29%, p = 0.025) and survival (p = 0.001). The aim of the present study was to establish whether decreasing the dosage of epirubicin to 150 mg/m2 would result in the same activity but with less hematological toxicity. One hundred fifty-nine patients with advanced soft tissue sarcoma were randomized for either epirubicin 150 mg/m2-cisplatin 120 mg/m2 (group A) or epirubicin 180 mg/m2-cisplatin 120 mg/m2 (group B). The results were as follows: group A: 79 patients were evaluated. Overall response rate was 24/79 (30%) (95% CI 21-41%). Median survival was 11 months and probability of survival at 1 year was 0.46. Grade IV granulocytopenia was present in 111/274 cycles and febrile neutropenia in 22/274. Group B: 73 patients were evaluated. The overall response rate was 39/73 (53%), (95% CI 42-64%). Median survival was 14 months and probability of survival at 1 year was 0.58. Grade IV granulocytopenia was present in 136/295 cycles and febrile neutropenia in 30/295. The differences were as follows: for overall response rate p = 0.004; power (for p = 0.05) 85%; for survival p = 0.09; for grade IV granulocytopenia p = 0.3; and for febrile neutropenia p = 0.61. A survival advantage (p = 0.043) was evident for patients randomized to group B and with performance status 0 or 1 compared with similar patients from group A. A plateau-like formation on the probability level of 0.26 on the survival curve started from month 26 onwards. In conclusion, both regimens share the same toxicity but epirubicin 180 mg/m2-cisplatin seems more active in soft tissue sarcoma, possibly indicating a breakthrough for activity between an epirubicin dosage of 150 mg/m2 and 180 mg/m2 in combination with cisplatin. The superiority of the epirubicin 180 mg/m2-cisplatin regimen appears evident both in terms of response and survival." @default.
- W147146103 created "2016-06-24" @default.
- W147146103 creator A5005491386 @default.
- W147146103 creator A5011520496 @default.
- W147146103 creator A5036110395 @default.
- W147146103 creator A5044550074 @default.
- W147146103 creator A5066921586 @default.
- W147146103 creator A5077480645 @default.
- W147146103 creator A5078969423 @default.
- W147146103 date "1999-01-01" @default.
- W147146103 modified "2023-10-16" @default.
- W147146103 title "Epirubicin 150 mg/m2-cisplatin versus epirubicin 180 mg/m2-cisplatin for advanced soft tissue sarcoma." @default.
- W147146103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10939030" @default.
- W147146103 hasPublicationYear "1999" @default.
- W147146103 type Work @default.
- W147146103 sameAs 147146103 @default.
- W147146103 citedByCount "0" @default.
- W147146103 crossrefType "journal-article" @default.
- W147146103 hasAuthorship W147146103A5005491386 @default.
- W147146103 hasAuthorship W147146103A5011520496 @default.
- W147146103 hasAuthorship W147146103A5036110395 @default.
- W147146103 hasAuthorship W147146103A5044550074 @default.
- W147146103 hasAuthorship W147146103A5066921586 @default.
- W147146103 hasAuthorship W147146103A5077480645 @default.
- W147146103 hasAuthorship W147146103A5078969423 @default.
- W147146103 hasConcept C126322002 @default.
- W147146103 hasConcept C136948725 @default.
- W147146103 hasConcept C141071460 @default.
- W147146103 hasConcept C142724271 @default.
- W147146103 hasConcept C2776283816 @default.
- W147146103 hasConcept C2776694085 @default.
- W147146103 hasConcept C2776755627 @default.
- W147146103 hasConcept C2777063308 @default.
- W147146103 hasConcept C2778239845 @default.
- W147146103 hasConcept C2778256501 @default.
- W147146103 hasConcept C2778629024 @default.
- W147146103 hasConcept C2778850193 @default.
- W147146103 hasConcept C2780835546 @default.
- W147146103 hasConcept C29730261 @default.
- W147146103 hasConcept C71924100 @default.
- W147146103 hasConcept C90924648 @default.
- W147146103 hasConceptScore W147146103C126322002 @default.
- W147146103 hasConceptScore W147146103C136948725 @default.
- W147146103 hasConceptScore W147146103C141071460 @default.
- W147146103 hasConceptScore W147146103C142724271 @default.
- W147146103 hasConceptScore W147146103C2776283816 @default.
- W147146103 hasConceptScore W147146103C2776694085 @default.
- W147146103 hasConceptScore W147146103C2776755627 @default.
- W147146103 hasConceptScore W147146103C2777063308 @default.
- W147146103 hasConceptScore W147146103C2778239845 @default.
- W147146103 hasConceptScore W147146103C2778256501 @default.
- W147146103 hasConceptScore W147146103C2778629024 @default.
- W147146103 hasConceptScore W147146103C2778850193 @default.
- W147146103 hasConceptScore W147146103C2780835546 @default.
- W147146103 hasConceptScore W147146103C29730261 @default.
- W147146103 hasConceptScore W147146103C71924100 @default.
- W147146103 hasConceptScore W147146103C90924648 @default.
- W147146103 hasIssue "4" @default.
- W147146103 hasLocation W1471461031 @default.
- W147146103 hasOpenAccess W147146103 @default.
- W147146103 hasPrimaryLocation W1471461031 @default.
- W147146103 hasRelatedWork W147146103 @default.
- W147146103 hasRelatedWork W1794992355 @default.
- W147146103 hasRelatedWork W2100986293 @default.
- W147146103 hasRelatedWork W2123895550 @default.
- W147146103 hasRelatedWork W2149843972 @default.
- W147146103 hasRelatedWork W2353768501 @default.
- W147146103 hasRelatedWork W2356463940 @default.
- W147146103 hasRelatedWork W2359665599 @default.
- W147146103 hasRelatedWork W2361360140 @default.
- W147146103 hasRelatedWork W3000137257 @default.
- W147146103 hasVolume "19" @default.
- W147146103 isParatext "false" @default.
- W147146103 isRetracted "false" @default.
- W147146103 magId "147146103" @default.
- W147146103 workType "article" @default.